May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 05, 2025

Ustekinumab Biosimilar Receives Interchangeability Approval

Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

January 10, 2025

Higher H. pylori Prevalence Seen in Severe Psoriasis

Psoriasis patients show higher Helicobacter pylori infection rates, with potential implications for further research into disease associations.

Conexiant

November 26, 2024

PsA Clusters Identified for Tailored Treatment: Longitudinal Study

A recent study reveals significant treatment response improvements in severe psoriatic arthritis and extensive psoriasis, emphasizing the need for personalized treatment strategies and sensitive outcome measures. (Source: Psoriatic Arthritis Research Consortium)

Conexiant

June 12, 2024

FAc Implant Shows Sustained Improvement in Uveitis

Long-term study highlights effectiveness of fluocinolone acetonide implant in managing non-infectious posterior uveitis, maintaining stable intraocular pressure.

Conexiant

March 21, 2025

FDA Approves Guselkumab for Crohn’s Disease

The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.

Conexiant